urea and imatinib mesylate

urea has been researched along with imatinib mesylate in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (11.76)	29.6817
2010's	8 (47.06)	24.3611
2020's	7 (41.18)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Breitenstein, W; Brüggen, J; Cowan-Jacob, SW; Furet, P; Manley, PW; Mestan, J; Meyer, T	1
Akizawa, T; Iyoda, M; Kawaguchi, M; Shibata, T; Yamaoka, T	1
Ashihara, E; Kimura, S; Lyons, JF; Maekawa, T; Nagao, R; Ottmann, OG; Reule, M; Smyth, T; Squires, MS; Takeuchi, M; Tanaka, R; Thompson, NT; Yamauchi, T; Yao, H; Yokota, A	1
Brdar, I; Deng, X; Faessler, R; Mani, NS; Roessler, A; Sales, ZS; Wu, J	1
Gallipoli, P; Holyoake, T; Jørgensen, H; Lyons, J; Shah, M	1
Fang, Z; Hong, S; Hong, SS; Jung, KH; Kim, J; Kim, SJ; Lee, H; Shin, S; Son, MK; Yan, HH; Yun, SM	1
Fang, Z; Hong, S; Hong, SS; Jung, KH; Kim, J; Kim, SJ; Lee, H; Lee, S; Lim, JH; Ryu, YL; Son, MK; Suh, JK; Yan, HH	1
Jin, J; Lei, H; Li, X; Liu, M; Luo, H; Wu, Y; Xu, H; Yang, L	1
Chang, JY; Chen, CT; Chen, LT; Hsu, T; Hsueh, CC; Jiaang, WT; Kung, FC; Lee, LC; Lin, HY; Lin, WH; Lu, CT; Peng, YH; Shiao, HY; Song, JS; Su, YC; Tsai, HJ; Tu, CH; Wang, PC; Wu, SY; Wu, TS; Yeh, TK	1
Achour, H; Bauer, S; Blay, JY; Choucair, K; Gelderblom, H; George, S; Heinrich, MC; Mehren, MV; Nemunaitis, J; Ruiz-Soto, R; Schöffski, P; Zalcberg, J	1
George, S; Serrano, C	1
Dong, Z; Li, J	1
Li, X; Meade, J; Ruiz-Soto, R; Shelton, MJ; Wang, J	1
Cai, S; Cao, H; Deng, Y; Dong, J; Huang, Z; Li, J; Shen, L; Wu, X; Zhang, J; Zhou, Y	1
Goggin, C; Huang, P; Jones, RL; Mahalingam, P; Napolitano, A; Smith, MJ; Stansfeld, A; Thway, K	1
Charlab, R; Doros, L; Fashoyin-Aje, LA; Kumar, V; Lemery, SJ; Mushti, SL; Pazdur, R; Spehalski, EI; Tang, S; Theoret, MR; Thompson, M; Thompson, MD; Zhao, H	1

Reviews

2 review(s) available for urea and imatinib mesylate

Article	Year
Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19 Topics: Apoptosis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Triazines; Urea	2020
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval. Future oncology (London, England), 2022, Volume: 18, Issue:26 Topics: Antineoplastic Agents; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Urea	2022

Article

Year

Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19

Topics: Apoptosis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Triazines; Urea

2020

Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.

Future oncology (London, England), 2022, Volume: 18, Issue:26

Topics: Antineoplastic Agents; Drug Approval; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Naphthyridines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Urea

2022

Trials

3 trial(s) available for urea and imatinib mesylate

Article	Year
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future oncology (London, England), 2020, Volume: 16, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Naphthyridines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Research Design; Sunitinib; Survival Rate; Urea; Young Adult	2020
Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 08-15, Volume: 28, Issue:16 Topics: China; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Sunitinib; Urea	2022
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 06-01, Volume: 29, Issue:11 Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Urea	2023

Other Studies

12 other study(ies) available for urea and imatinib mesylate

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorganic & medicinal chemistry letters, 2004, Dec-06, Volume: 14, Issue:23 Topics: Animals; Benzamides; Cell Line, Tumor; Genes, abl; Humans; Imatinib Mesylate; Mice; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Urea	2004
Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney international, 2009, Volume: 75, Issue:10 Topics: Animals; Basement Membrane; Benzamides; Creatinine; Glomerulonephritis; Imatinib Mesylate; Kidney Glomerulus; Macrophages; Piperazines; Protective Agents; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome; Urea	2009
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood, 2010, Sep-23, Volume: 116, Issue:12 Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Urea	2010
Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3. The Journal of organic chemistry, 2011, Oct-21, Volume: 76, Issue:20 Topics: Amides; Amination; Aniline Compounds; Anticholesteremic Agents; Azabicyclo Compounds; Benzamides; Catalysis; Chemistry, Pharmaceutical; Erlotinib Hydrochloride; Eszopiclone; Fluorobenzenes; Heterocyclic Compounds; Humans; Hydrogen-Ion Concentration; Hypnotics and Sedatives; Hypoglycemic Agents; Imatinib Mesylate; Molecular Structure; Phosphorus Compounds; Piperazines; Prescription Drugs; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones; Urea	2011
Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood cells, molecules & diseases, 2012, Mar-15, Volume: 48, Issue:3 Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Benzimidazoles; Cell Line, Tumor; Cell Survival; Cells, Cultured; Humans; Imatinib Mesylate; Janus Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Urea	2012
HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer letters, 2014, Jun-28, Volume: 348, Issue:1-2 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzothiazoles; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Models, Molecular; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Tumor Burden; Urea	2014
HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Oncotarget, 2015, Jan-30, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Mutation; Piperazines; Random Allocation; Signal Transduction; Urea; Xenograft Model Antitumor Assays	2015
Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells. Leukemia research, 2018, Volume: 64 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Pyrazoles; Pyrimidines; Thiophenes; Urea; Xenograft Model Antitumor Assays	2018
Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants. Journal of medicinal chemistry, 2019, 04-25, Volume: 62, Issue:8 Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays	2019
[Current status and progress in novel drug research for gastrointestinal stromal tumors]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2020, Sep-25, Volume: 23, Issue:9 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Triazines; Urea	2020
Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:10 Topics: Adult; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Gastric Acid; Humans; Imatinib Mesylate; Itraconazole; Naphthyridines; Pantoprazole; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rifampin; Urea	2022